Finch clips wings of hepatitis B program, hitting pause on clinical plan to focus on C. diff and autism

Finch Therapeutics has joined the ranks of biotechs that are narrowing their focus. With its lead program under clinical hold, the microbiome specialist has pulled out of a planned study in chronic hepatitis B.